Streetbeat News

RHHBY

Roche Holding AG

CEO

Severin Schwan

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

42.57

Mkt cap

278B

Volume

213K

High

43.31

P/E Ratio

29.63

52-wk high

43.96

Low

42.56

Div yield

N/A

52-wk low

29.20

Roche's Genentech has provided an update on its Phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer. The study did not meet its primary endpoint of improving progression-free survival in people with PD-L1-high metastatic non-small cell lung cancer.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2023 | 5:57 am

The FDA has approved Regeneron Pharmaceuticals' Eylea HD Injection 8 mg for wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. This approval is seen as a shield against potential biosimilar competition. Truist Securities and BMO Capital remain bullish on Regeneron due to this approval. However, Regeneron is still involved in a lawsuit with Viatris regarding the potential introduction of their Eylea biosimilar. RBC Capital Markets has increased the price target for Regeneron from $820 to $830.

Portfolio Pulse from Vandana Singh

August 21, 2023 | 7:04 pm

Exelixis Inc, Roche Holdings AG, and Ipsen announced that their Phase 3 CONTACT-02 pivotal trial evaluating Cabometyx in combination with Tecentriq has met one of the primary endpoints, showing a significant improvement in progression-free survival. The trial is for patients with metastatic castration-resistant prostate cancer. The estimated total U.S. market value is approximately $1.9 billion. Analysts from William Blair maintain the Outperform rating on Exelixis' stock.

Portfolio Pulse from Vandana Singh

August 21, 2023 | 6:57 pm

Sonnet BioTherapeutics Holdings Inc's shares are trading higher after the company announced that the IND for SB221, the Phase 1b/2a trial of SON-1010 in combination with Roche Holding AG's atezolizumab, has been accepted. The study will begin in the U.S. for platinum-resistant ovarian cancer. The trial will establish the maximum tolerated dose of SON-1010 with a fixed dose of atezolizumab. SONN shares are up 23.78% at $0.40 at publication Wednesday.

Portfolio Pulse from Vandana Singh

August 16, 2023 | 4:00 pm

Aravive Inc's shares have plummeted after its Phase 3 AXLerate-OC trial for batiraxcept in platinum-resistant ovarian cancer failed to meet its primary endpoint. The trial showed no difference between the two arms in the overall population. The company will continue to evaluate the complete dataset and determine the next steps in developing batiraxcept. William Blair analysts have downgraded Aravive shares to a Market Perform rating due to a lack of significant upcoming clinical milestones and limited cash runway.

Portfolio Pulse from Vandana Singh

August 04, 2023 | 1:00 pm

Pharmaceutical companies, including Johnson & Johnson, Merck & Co Inc, and Halozyme Therapeutics Inc, anticipate that reformulated injectable versions of some popular treatments will not be included in U.S. government price negotiations for several years, safeguarding substantial revenue. They argue that modifying the formula of intravenous medications to allow for injectable use qualifies them as new drugs, delaying their price negotiation eligibility. Bristol Myers Squibb & Co and Roche Holdings AG, developing under-the-skin injections of cancer immunotherapies, stated that it's premature to comment.

Portfolio Pulse from Vandana Singh

July 28, 2023 | 5:47 pm

Roche Holding AG reported a decline in 1H 2023 sales to CHF 30.62 billion from CHF 33.9 billion in the same period last year, due to the tapering of demand for COVID-19 tests. The company's CFO, Alan Hippe, highlighted the need for superior drug development projects in later stages to enhance the company's stock market value. He also noted that the company's share price was negatively impacted due to the decline in COVID-19-related demand.

Portfolio Pulse from Vandana Singh

July 27, 2023 | 2:58 pm

The World Health Organization (WHO) has published new editions of the Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc), which include new medicines for various diseases. However, Novo Nordisk's obesity drug Saxenda was not included due to uncertain long-term clinical benefit and safety. Other drugs included in the list are from EMD Serono, Merck KGaA, Teva Pharmaceuticals, Roche Holdings, Ridgeback Biotherapeutics, and Regeneron Pharmaceuticals.

Portfolio Pulse from Vandana Singh

July 26, 2023 | 2:24 pm

AT&T and Verizon face investor skepticism over lead-cable issue and debt load. Adidas receives orders worth $565M for unsold Yeezy inventory. IAC and publishers form coalition to address AI platform concerns. Tesla plans to meet India's commerce minister to discuss factory plans. Spotify raises prices for its premium plans in the U.S. CME Group plans to terminate 3% of workforce. Domino's Pizza reports a sales decline in Q2. Chevron releases Q2 results and announces management changes. Philips reports Q2 sales growth. Alnylam enters agreement with Roche for hypertension therapy. FDA approves BD's Alaris Infusion System. ViiV Healthcare's cabotegravir secures European backing for approval. IAG invests in Nova Pangaea Technologies.

Portfolio Pulse from Vandana Singh

July 24, 2023 | 2:07 pm

Alnylam Pharmaceuticals has entered a strategic agreement with Roche Holdings to develop and commercialize zilebesiran, a treatment for hypertension currently in Phase 2 of development. Alnylam will receive an upfront cash payment of $310 million and is eligible for additional payments, including development milestone payments over the next few years, as well as regulatory and sales milestones, for a potential deal value of up to $2.8 billion. Alnylam and Roche will co-commercialize zilebesiran in the U.S., with Roche having exclusive rights to commercialize outside the U.S.

Portfolio Pulse from Vandana Singh

July 24, 2023 | 12:51 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.